Is Tesamorelin FDA Approved? Full Regulatory History & Off-Label Facts

The trans-3-hexenoic acid modification at position 1 is not cosmetic chemistry. Natural GHRH(1-44) has a plasma half-life under 7 minutes because dipeptidyl peptidase IV (DPP-IV) rapidly cleaves it. Sermorelin (GRF 1-29) improved on this slightly but still has a half-life of roughly 10 to 12 minutes. Tesamorelin's chemical shield extends that to 26 minutes, long enough for a single daily injection to produce a full GH pulse.

CJC-1295 with DAC took a different approach: it attaches a Drug Affinity Complex that binds to albumin, extending the half-life to roughly 6 to 8 days. The trade-off is that CJC-1295 with DAC produces a sustained, non-pulsatile GH elevation that does not mimic natural physiology. Tesamorelin occupies a middle ground: long enough to work, short enough to maintain pulsatility.

For detailed comparisons, see tesamorelin vs CJC-1295, tesamorelin vs ipamorelin, and the full tesamorelin vs sermorelin vs ipamorelin breakdown.

Theratechnologies (originally Theralogics) began clinical development of tesamorelin (then designated TH9507) in the early 2000s. The target indication was HIV-associated lipodystrophy, a disfiguring condition where antiretroviral therapy causes pathological redistribution of body fat, particularly accumulating visceral fat around abdominal organs.

Phase 2 dose-ranging studies established that 2 mg/day subcutaneous injection produced optimal visceral fat reduction with an acceptable safety profile. Higher doses did not significantly improve efficacy, consistent with the pituitary's self-limiting GH release mechanism.

Two pivotal Phase 3 trials enrolled a combined 816 HIV-positive adults with documented lipodystrophy:

• Trial 1 (SEROST-0502): 412 participants, 26 weeks, tesamorelin 2 mg vs. placebo. Visceral adipose tissue (VAT) decreased by 15.2% in the tesamorelin group versus 5.0% in the placebo group (P < 0.001) (Falutz et al., NEJM 2007).
• Trial 2 (SEROST-0504): 404 participants, 26 weeks, similar design. VAT decreased by 18.4% with tesamorelin versus 2.2% with placebo (P < 0.001) (Falutz et al., J Clin Endocrinol Metab 2010).

Combined analysis showed that 69% of tesamorelin-treated participants achieved a clinically meaningful VAT reduction of 8% or greater, compared to 33% of placebo recipients. Trunk fat, waist circumference, and waist-to-hip ratio all improved. Subcutaneous fat and limb fat did not change, confirming that tesamorelin selectively targets visceral deposits.

The FDA approved tesamorelin for injection (brand name Egrifta) on November 10, 2010, under BLA (Biologics License Application) 022505. The approved indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

The original formulation required daily reconstitution of two vials (one containing tesamorelin powder, one containing sterile water for injection) to achieve the 2 mg dose. Patients mixed the solution fresh each morning and injected subcutaneously into the abdomen.

Key label details from the original approval:

• Dosing: 2 mg subcutaneous injection once daily
• Contraindications: Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumor/surgery; active malignancy; pregnancy; known hypersensitivity to tesamorelin or mannitol
• Warnings: Fluid retention, potential glucose metabolism changes, hypersensitivity reactions, injection site reactions
• Monitoring: IGF-1 levels at baseline and during treatment; discontinuation recommended if no improvement in lipodystrophy after 26 weeks

The approval was a milestone for the peptide therapy field. Before Egrifta, the only option for HIV lipodystrophy was cosmetic procedures or switching antiretroviral regimens, neither of which addressed the metabolic consequences of visceral fat accumulation.

In 2019, the FDA approved a reformulation called Egrifta SV (Single Vial). This version simplified the reconstitution process by packaging tesamorelin as a single vial requiring only one reconstitution step instead of two. The dose remained 2 mg/day. The clinical data, efficacy, and safety profile were unchanged.

Egrifta SV reduced preparation time from approximately 5 minutes (two-vial mixing) to under 2 minutes. For patients injecting daily, that convenience improvement mattered for long-term adherence.

On March 25, 2025, the FDA approved the supplemental Biologics License Application for Egrifta WR (Weekly Reconstitution), also called the F8 formulation. This represented the most significant formulation change since original approval.

Egrifta WR contains 11.6 mg of tesamorelin per vial, enough for seven daily doses after a single reconstitution. The daily injection dose is 1.28 mg (0.16 mL of the reconstituted solution) rather than the original 2 mg, reflecting improved bioavailability from the concentrated formulation. Once reconstituted, the solution remains stable for seven days at room temperature (20 to 25 degrees Celsius).

The practical benefits are substantial:

• Weekly reconstitution instead of daily: one preparation session per week
• 50% smaller injection volume compared to Egrifta SV
• Room temperature storage after reconstitution (no refrigeration needed)
• Four single-patient-use vials per monthly supply

For patients and clinicians managing tesamorelin dosage for fat loss, the WR formulation maintains the same clinical efficacy while reducing treatment burden. The availability of Egrifta WR through specialty pharmacies began in September 2025.

HIV-associated lipodystrophy is a metabolic syndrome that develops in a substantial percentage of patients on long-term antiretroviral therapy (ART). It manifests as abnormal fat redistribution: visceral fat accumulates around abdominal organs while subcutaneous fat wastes from the face, limbs, and buttocks. The visceral fat accumulation is not merely cosmetic. It drives insulin resistance, dyslipidemia, elevated cardiovascular risk, and non-alcoholic fatty liver disease.

Before tesamorelin, physicians had limited options. Switching ART regimens sometimes helped but risked viral resistance. Metformin and thiazolidinediones showed modest effects on visceral fat in this population. Growth hormone itself reduced visceral fat but caused unacceptable rates of insulin resistance and fluid retention at the doses needed.

Tesamorelin solved the GH problem. By stimulating endogenous pulsatile GH release rather than delivering supraphysiological GH directly, it reduced visceral fat by 15 to 18% over 26 weeks without the metabolic penalties of exogenous GH. The Phase 3 data was clean enough that the FDA approved it as the first and still only medication specifically indicated for HIV lipodystrophy.

The label specifies that treatment should be reassessed after 26 weeks. If a patient shows no meaningful improvement in lipodystrophy by that point, the prescribing information recommends discontinuation. In practice, most responders see measurable VAT reduction within 12 weeks, which aligns with the timeline data from both pivotal trials.

The FDA did not approve tesamorelin for:

• General weight loss or obesity
• Bodybuilding or athletic performance enhancement
• Anti-aging or longevity
• Non-alcoholic fatty liver disease (NAFLD) in non-HIV patients
• Cognitive enhancement or neuroprotection
• Growth hormone deficiency (adult or pediatric)

This distinction matters because every single one of those use cases has published research supporting tesamorelin's potential. A randomized trial in Lancet HIV showed tesamorelin reduced liver fat by 37% in HIV patients with NAFLD, with 35% of treated patients dropping below the 5% hepatic fat threshold that defines NAFLD (Stanley et al., Lancet HIV 2019). A controlled trial published in Archives of Neurology found that 20 weeks of GHRH analog administration improved executive function in both healthy older adults and those with mild cognitive impairment (Baker et al., Arch Neurol 2012).

The research is promising. But "promising research" and "FDA approved" are different regulatory categories, and conflating them is a common source of confusion in the peptide space. For a broader perspective on peptide legality and the difference between approved and research compounds, that guide covers the full landscape.

Once the FDA approves a drug for any indication, a licensed physician can legally prescribe it for any condition they judge medically appropriate for their patient. This is called off-label prescribing, and it accounts for roughly 20% of all prescriptions written in the United States.

Off-label prescribing is not a loophole. It is a recognized, legal component of medical practice. The FDA regulates drug approval and marketing, but it does not regulate the practice of medicine. A physician who prescribes tesamorelin for visceral fat reduction in a non-HIV patient is exercising clinical judgment within the bounds of their medical license.

Here is what off-label prescribing requires:

1. 1.A valid patient-physician relationship. Telemedicine consults qualify, but the relationship must be genuine and documented.
2. 2.Medical justification. The physician must have a reasonable clinical basis for believing the drug will benefit the patient. For tesamorelin, the Phase 3 visceral fat reduction data provides that basis.
3. 3.Informed consent. The patient must understand that the use is off-label and that the specific indication has not been evaluated by the FDA.
4. 4.A legitimate prescription. The prescription must be filled through a licensed pharmacy (retail or specialty).

What off-label prescribing does not cover: purchasing tesamorelin from research chemical suppliers without a prescription, self-administering without medical oversight, or importing from overseas pharmacies without FDA authorization.

Following the FDA peptide crackdown of 2026, the distinction between FDA-approved and non-approved peptides became sharper. The FDA moved several popular peptides, including BPC-157 and various GH secretagogues, off the Category 2 compounding list, restricting their availability through compounding pharmacies.

Tesamorelin was not affected by this crackdown because it holds active FDA approval. This is the practical benefit of regulatory status: when enforcement tightens, approved compounds remain accessible through standard prescription channels while unapproved compounds face supply disruptions.

The current off-label prescribing landscape for tesamorelin includes:

• Anti-aging clinics prescribing it for visceral fat reduction in non-HIV patients
• Hormone optimization practices combining it with other GH secretagogues (commonly ipamorelin) for synergistic effects
• Hepatology research exploring its effects on NAFLD in non-HIV populations
• Neurology research investigating cognitive protection in aging populations

For patients comparing tesamorelin to other GH peptides that may be harder to access, see tesamorelin vs ipamorelin and tesamorelin vs sermorelin vs ipamorelin. The sermorelin for fat loss guide covers another GHRH analog with a different regulatory history.

FDA approval does not automatically mean insurance coverage. Most insurers cover Egrifta only for the on-label indication (HIV lipodystrophy) and require prior authorization demonstrating:

• Confirmed HIV diagnosis on antiretroviral therapy
• Documented lipodystrophy with excess visceral fat
• CT or MRI evidence of visceral adiposity
• Failure of other interventions (in some plans)

Off-label prescriptions for non-HIV patients are almost universally denied by insurance. Out-of-pocket cost for brand-name Egrifta runs approximately $1,500 to $2,500 per month at retail pricing. Some specialty pharmacies and manufacturer assistance programs reduce this for qualifying patients.

Compounded tesamorelin, available through 503B outsourcing facilities, costs significantly less (typically $200 to $600 per month) but does not carry the brand-name label. The compounded version uses the same active molecule but is not FDA-verified for bioequivalence. For a cost comparison across GH peptides, use our peptide cost calculator.

The two Phase 3 trials were randomized, double-blind, placebo-controlled studies conducted across multiple centers. Both used CT scan measurements of visceral adipose tissue area at the L4-L5 vertebral level, the gold standard for quantifying visceral fat.

Combined results (816 participants):

The selectivity of the fat reduction was notable. Tesamorelin reduced visceral fat without depleting the subcutaneous fat or limb fat that HIV patients were already losing from lipodystrophy. This selectivity comes from the higher density of beta-adrenergic receptors in visceral adipose tissue, which makes it more responsive to GH-mediated lipolysis (Moller & Jorgensen, Endocr Rev 2009).

For detailed dosing from these trials, see the tesamorelin dosage for fat loss guide. To understand how these results compare to the CJC-1295 + ipamorelin dosage calculator protocols, that tool provides side-by-side dosing estimates.

The Phase 3 trials included 52-week extension phases where participants who responded at 26 weeks continued treatment. This extension data was critical for FDA reviewers assessing sustained efficacy and long-term safety.

Key findings from the 52-week data:

• VAT reduction was maintained through week 52 in participants who continued tesamorelin. Those who switched to placebo at week 26 regained visceral fat, returning to near-baseline levels by week 52, confirming that the effect requires ongoing treatment (Falutz et al., J Clin Endocrinol Metab 2010).
• Metabolic markers improved in sustained responders. Triglycerides decreased, adiponectin increased, and glucose homeostasis remained stable over the full year.
• IGF-1 levels stabilized. The initial increase in IGF-1 (expected with any GH-stimulating therapy) plateaued within normal range by week 12 and remained stable through week 52, confirming the pituitary feedback loop was functioning correctly.
• No new safety signals emerged between week 26 and week 52. The adverse event profile in the extension phase matched the initial 26-week data.

The fat regain after discontinuation is an important clinical detail. Tesamorelin does not permanently restructure fat distribution. It maintains reduced visceral fat as long as treatment continues, similar to how statin therapy maintains cholesterol reduction only during active use.

Although not part of the original FDA approval package, subsequent controlled trials expanded the evidence for tesamorelin's metabolic benefits. The most significant was a randomized, double-blind, multicenter trial examining tesamorelin's effect on non-alcoholic fatty liver disease in HIV patients.

Stanley et al. (Lancet HIV, 2019): 61 HIV-infected men and women with hepatic fat fraction of 5% or greater (defined as NAFLD) were randomized to tesamorelin 2 mg/day or placebo for 12 months.

Results: - Hepatic fat fraction decreased by 37% (absolute effect: -4.1%, P = 0.02) in the tesamorelin group versus placebo - 35% of tesamorelin-treated patients dropped below the 5% threshold, resolving their NAFLD classification, versus 4% of placebo patients - Fibrosis progression was substantially attenuated in the tesamorelin group - Hepatic expression of genes involved in oxidative phosphorylation increased, while genes for inflammation and tissue repair decreased

(Stanley et al., Lancet HIV 2019)

These findings are relevant because visceral fat and liver fat are metabolically linked. Tesamorelin's ability to reduce both suggests that its mechanism operates at the level of hepatic and visceral lipid metabolism, not just peripheral fat mobilization. This data supports the off-label use case but has not led to a label expansion because the study was conducted exclusively in HIV patients.

A separate line of research, unrelated to the HIV lipodystrophy indication, has explored GHRH analog effects on brain function. Growth hormone and IGF-1 have established roles in neurogenesis, synaptic plasticity, and neuroprotection, and GHRH receptors are expressed throughout the central nervous system.

Baker et al. (Archives of Neurology, 2012): 152 adults (76 healthy older adults and 76 with mild cognitive impairment) were randomized to 20 weeks of tesamorelin or placebo. Tesamorelin improved executive function (task switching accuracy, Stroop interference, verbal fluency) in both groups. Adults with MCI showed preserved cognitive scores where the placebo group declined. GABA levels increased across multiple brain regions in treated participants (Baker et al., Arch Neurol 2012).

A follow-up MRI study found that tesamorelin preserved hippocampal volume compared to placebo, consistent with IGF-1's known role in promoting neurogenesis and reducing neuronal apoptosis in the hippocampus.

These findings have not been pursued for FDA approval. The trial was relatively small and short, and the FDA would require larger, longer Phase 3 trials with defined cognitive endpoints to consider an approval for this indication. But the data adds another dimension to tesamorelin's evidence base that no other GH peptide can claim.

The most frequently reported adverse events in clinical trials, compared to placebo:

The overall discontinuation rate due to adverse events was 6.8% for tesamorelin versus 3.2% for placebo. No treatment-related deaths occurred in any clinical trial.

For context on how these rates compare to other growth hormone peptides, see is sermorelin safe, which shows similar adverse event patterns at lower frequencies (consistent with sermorelin's shorter half-life and lower potency).

The FDA's primary safety concern with tesamorelin was its effect on glucose metabolism. Growth hormone is a counter-regulatory hormone that opposes insulin action, and any therapy that raises GH levels carries theoretical risk of insulin resistance and diabetes.

The data showed a real but modest signal. In Phase 3 trials, 5% of tesamorelin-treated patients developed HbA1c levels of 6.5% or greater (the diabetes threshold) compared to 1% of placebo patients, yielding a hazard ratio of 3.3 for incident diabetes. However, the absolute risk increase was 4%, and most cases were in patients with pre-existing glucose impairment at baseline.

The label includes a specific warning: "EGRIFTA may cause glucose intolerance. Evaluate glucose status before initiating and monitor periodically during therapy."

In practice, this means:

• Baseline HbA1c and fasting glucose before starting treatment
• Repeat testing at 12 and 26 weeks
• Closer monitoring for patients with pre-existing insulin resistance, metabolic syndrome, or family history of type 2 diabetes
• Consider discontinuation if HbA1c exceeds 6.5% without pre-existing diabetes

The 52-week extension data showed that glucose changes stabilized after the initial 26-week period. Long-term tesamorelin users who maintained normal glucose at 26 weeks generally remained stable through 52 weeks (Falutz et al., 2010).

This glucose signal is one reason tesamorelin is not a casual addition to a body composition protocol. It requires monitoring, which brings us back to the importance of physician oversight for off-label use.

The FDA label lists the following contraindications:

• Active malignancy. GH and IGF-1 can promote cell proliferation. Any active cancer is an absolute contraindication. Patients with a history of cancer should wait until cleared by their oncologist. This concern applies equally to all GH-stimulating peptides, not just tesamorelin.
• Disruption of the hypothalamic-pituitary axis. Patients who have had pituitary surgery, radiation to the pituitary region, or diagnosed hypopituitarism will not respond to tesamorelin because the mechanism requires a functioning pituitary. These patients need exogenous GH, not a GH secretagogue.
• Pregnancy. Tesamorelin is classified as pregnancy category X. It should not be used during pregnancy, and pregnancy testing is recommended before initiation in women of reproductive age.
• Known hypersensitivity to tesamorelin or mannitol (used as an excipient in the formulation).

Drug interactions of clinical significance:

• Glucocorticoids (prednisone, dexamethasone): May blunt the GH response to tesamorelin
• Insulin and oral hypoglycemics: Dose adjustment may be needed due to tesamorelin's effect on glucose metabolism
• 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1): GH inhibits this enzyme, potentially reducing cortisone-to-cortisol conversion. Patients on cortisone replacement may need dose adjustments.

For broader drug interaction screening across peptides, use our peptide interaction checker.

Sermorelin (GRF 1-29) had FDA approval from 1997 to 2008 under the brand name Geref, indicated for diagnosing GH deficiency in children. EMD Serono voluntarily withdrew it in 2008 for commercial reasons, not safety concerns.

Sermorelin is still available through compounding pharmacies but has no active FDA approval. Its clinical safety record is strong (decades of human use data, multiple controlled trials), but the evidence base is smaller than tesamorelin's for fat reduction.

The practical difference: tesamorelin can be prescribed through standard specialty pharmacies with an active FDA-approved label. Sermorelin requires compounding pharmacy sourcing, which is subject to varying state regulations and the evolving FDA peptide crackdown enforcement landscape.

For a full comparison, see tesamorelin vs sermorelin vs ipamorelin and sermorelin for fat loss.

CJC-1295 is a modified GHRH analog that has never received FDA approval for any indication. It exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also called modified GRF 1-29 or MOD-GRF 1-29).

The DAC version extends the half-life to 6 to 8 days, producing sustained GH elevation rather than pulsatile release. The FDA reviewed CJC-1295 with DAC for its Pharmacy Compounding Advisory Committee in 2024 and it was removed from the Category 2 compounding list, making it unavailable through standard compounding channels in the US.

CJC-1295 has no Phase 3 trial data, no long-term human safety studies, and no FDA-verified manufacturing standards. The evidence for its efficacy comes from Phase 1/2 data and clinical observation.

For detailed head-to-head analysis, see tesamorelin vs CJC-1295. To estimate dosing for CJC-1295 combinations, use the CJC-1295 + ipamorelin dosage calculator.

Ipamorelin is a growth hormone secretagogue (GHS) that works through a different receptor than tesamorelin. While tesamorelin stimulates GHRH receptors, ipamorelin activates ghrelin receptors (GHS-R) on pituitary somatotrophs. The two mechanisms are complementary, which is why some protocols combine them.

Ipamorelin has never received FDA approval. It was on the FDA's Category 2 compounding list but was removed in September 2024, similar to CJC-1295. Its availability through compounding pharmacies is uncertain and varies by state.

The evidence base for ipamorelin consists of Phase 1/2 studies primarily focused on GI motility (post-surgical ileus), not body composition. No randomized controlled trials have measured ipamorelin's effect on visceral fat with CT scan endpoints comparable to the tesamorelin Phase 3 program.

For a direct comparison, see tesamorelin vs ipamorelin.

HGH Fragment 176-191 is a modified fragment of the growth hormone molecule (amino acids 176-191) that is purported to stimulate lipolysis without the full spectrum of GH effects. It has never received FDA approval, has no published Phase 3 data, and is available only through research suppliers and some compounding pharmacies.

The fragment does not stimulate GH release from the pituitary. It does not raise IGF-1 levels. Its mechanism is fundamentally different from tesamorelin: rather than working through the GH axis, it is thought to interact directly with fat cell receptors. The evidence for its efficacy is limited to in vitro studies and animal models, with no controlled human trials published in peer-reviewed journals.

From a regulatory perspective, HGH Fragment 176-191 occupies the weakest position among commonly discussed fat loss peptides: no FDA approval, no clinical trial data, and uncertain legal status.

Starting in late 2024 and accelerating through 2025 and into 2026, the FDA tightened enforcement on compounded peptides. The agency removed several popular compounds from the Category 2 bulk drug substance list, which governs what 503A and 503B compounding pharmacies can legally produce.

Compounds affected include BPC-157, CJC-1295, ipamorelin, and several others commonly prescribed in anti-aging and body composition protocols. The full FDA peptide crackdown analysis covers the specific compounds, timelines, and implications.

Tesamorelin was unaffected by this crackdown because its regulatory pathway is different. As an FDA-approved biologic with an active BLA, it is manufactured by Theratechnologies under cGMP standards and distributed through legitimate specialty pharmacy channels. The compounding restrictions do not apply to FDA-approved products.

This creates a practical two-tier system:

For patients who relied on non-approved GH secretagogues that are now harder to source, tesamorelin (via off-label prescription) represents the most pharmacologically similar alternative with a secure supply chain.

FDA approval guarantees four things:

1. 1.Efficacy for the approved indication has been demonstrated in controlled trials meeting pre-specified endpoints.
2. 2.Safety has been characterized across a defined patient population with documented adverse events, contraindications, and monitoring requirements.
3. 3.Manufacturing is controlled. Every batch meets identity, purity, potency, and sterility standards verified by the FDA.
4. 4.Post-market surveillance continues. Adverse events after approval are tracked through the FDA Adverse Event Reporting System (FAERS), and the manufacturer is required to update the label if new safety signals emerge.

What FDA approval does not guarantee:

• Efficacy for off-label uses. The Phase 3 data applies to HIV lipodystrophy. Extrapolating to general visceral fat reduction is reasonable (the biology is the same) but not FDA-verified.
• Safety in all populations. The trials enrolled HIV-positive adults. Safety in non-HIV populations, pediatric patients, or elderly populations with comorbidities was not specifically studied in the approval program.
• Superiority over alternatives. FDA approval means the drug works better than placebo for its indication. It does not mean it is the best option for every patient.

For a comprehensive understanding of peptide legality across different regulatory categories, that resource provides the current framework.

On-label (HIV lipodystrophy): An HIV specialist or infectious disease physician documents the lipodystrophy diagnosis, submits prior authorization to the patient's insurer, and writes the prescription for Egrifta WR. Specialty pharmacies like CuraScript, Accredo, or Optum handle fulfillment. Insurance typically covers this after prior authorization approval.

Off-label (general visceral fat reduction): An endocrinologist, anti-aging physician, or hormone optimization clinic evaluates the patient, orders baseline labs (IGF-1, HbA1c, fasting glucose, comprehensive metabolic panel), and writes the prescription. The physician must document the clinical rationale. The prescription goes to a specialty pharmacy or a 503B outsourcing facility that compounds tesamorelin.

Telemedicine clinics: Several national telemedicine platforms now prescribe tesamorelin off-label for visceral fat reduction. These typically require lab work (either provided by the patient or ordered through a partner lab), a video consultation with a licensed prescriber, and ongoing monitoring labs at defined intervals.

Regardless of the pathway, physician oversight is non-negotiable for tesamorelin. The glucose metabolism effects alone require baseline and follow-up monitoring that self-directed use cannot safely provide.

Brand-name Egrifta WR is manufactured by Theratechnologies under FDA-audited cGMP conditions. Each vial is verified for potency, purity, and sterility. The cost is higher ($1,500 to $2,500/month without insurance) but the product reliability is guaranteed.

Compounded tesamorelin is produced by 503B outsourcing facilities using bulk tesamorelin active pharmaceutical ingredient (API). Compounded versions are legal because tesamorelin has FDA approval (the compound itself is not restricted, only the brand-name product has exclusivity for the specific formulation). Compounded tesamorelin typically costs $200 to $600/month.

The trade-off is quality assurance. 503B facilities are FDA-registered and inspected, but the inspection frequency and depth is less rigorous than for branded pharmaceutical manufacturing. API sourcing varies. Some 503B facilities use U.S.-sourced API with certificates of analysis; others source from overseas with less transparent supply chains.

For patients choosing compounded tesamorelin, look for: - 503B registration (not just 503A) - U.S.-sourced API with third-party testing certificates - Sterility testing on every batch (not just periodic) - A reconstitution calculator to verify accurate dosing: use our peptide reconstitution calculator

For broader guidance on sourcing peptides safely, the is sermorelin safe article covers similar considerations for another GH-releasing peptide.